RDX013 / Ardelyx - LARVOL DELTA

Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (clinicaltrials.gov) - P2 | N=109 | Completed | Sponsor: Ardelyx | Active, not recruiting ➔ Completed

Trial completion

Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: Ardelyx; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2021 ➔ Mar 2022

Clinical • Enrollment closed • Trial completion date

[VIRTUAL] RDX013, a Novel, Oral, Small Molecule Being Developed for Treatment of Hyperkalemia, Increases Colonic Secretion and Fecal Excretion of Potassium (KIDNEY WEEK 2021) - P2 | "Conclusion Based on its unique mechanism of action which involves pharmacologically enhancing K + secretion through apical K + channels in the colon, RDX013 is a potential first-in-class therapy which may provide a new approach to managing serum K + in patients versus commonly prescribed K + binders. A phase 2 clinical study with RDX013 (NCT04780841) is ongoing in non-dialysis CKD patients with hyperkalemia."

Atrial Fibrillation • Cardiovascular

Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Ardelyx

Clinical • New P2 trial